World Journal of Surgery

, Volume 30, Issue 5, pp 752–758 | Cite as

Classical and Follicular Variant of Papillary Thyroid Carcinoma: A Comparative Study on Clinicopathologic Features and Long-term Outcome

  • Brian Hung-Hin Lang
  • Chung-Yau LoEmail author
  • Wai-Fan Chan
  • Alfred King-Yin Lam
  • Koon-Yat Wan



The follicular variant of papillary thyroid carcinoma (FVPTC) is the most common histologic subtype of papillary thyroid carcinoma (PTC). However, it is still controversial whether FVPTC should behave differently from classical PTC (CPTC). The present study aimed at evaluating any potential difference in clinicopathologic features and long-term outcome of FVPTC as compared with CPTC.

Patients and Methods

Of 568 patients with PTC managed from 1973 to 2004, 308 were shown to have CPTC (54.2%) and 67 (11.8%) FVPTC after histologic review. The mean (± SD) follow-up period was 11.3 (± 8.9) years. The two groups were compared in terms of clinicopathological features, treatment received, and outcome regarding recurrence and disease-specific survival.


There was no difference in age and gender ratio between the CPTC and FVPTC patients. Both groups had similar tumor characteristics in terms of tumor size, presence of multifocality, capsular invasion, lymphovascular permeation, and perineural infiltration. However, FVPTC patients had significantly fewer histologically confirmed cervical lymph node metastases (P = 0.027) and extrathyroidal involvement (P = 0.005). The proportion of bilateral resection, adjuvant radioactive iodine, and lymph node dissection did not differ significantly between the two groups. The FVPTC patients had a more favorable tumor risk by DeGroot classification (P = 0.003) and MACIS (Metastasis, Age, Completeness of excision, Invasiveness, and Size) score (P = 0.026). The 10- and 15-year actuarial disease-specific survivals did not differ significantly between FVPTC and CPTC patients (96.2% versus 90.7% and 96.2% versus 89.1%, respectively).


Although patients with FVPTC had more favorable clinicopathologic features and a better tumor risk group profile, their long-term outcome was similar to that of CPTC patients.


Papillary Thyroid Carcinoma Papillary Carcinoma Radioactive Iodine Extrathyroidal Extension Follicular Variant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Tielens ET, Sherman SI, Hruban RH, et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study. Cancer 1994;73:424–431PubMedGoogle Scholar
  2. 2.
    Ortiz Sebastian S, Rodriguez Gonazles JM, Parilla Paricio P, et al. Papillary thyroid carcinoma: prognostic index for survival including the histological variety. Arch Surg 2000;135:272–277CrossRefGoogle Scholar
  3. 3.
    Zidan J, Karen D, Stein M, et al. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 2003;97:1181–1185CrossRefPubMedGoogle Scholar
  4. 4.
    Crile GJ, Hazard JB. Relationship of the age of the patient to the natural history and prognosis of carcinoma of the thyroid. Ann Surg 1953:138:33–38PubMedGoogle Scholar
  5. 5.
    Passler C, Prager G, Scheuba C, et al. Follicular variant of papillary thyroid carcinoma: a long-term follow-up. Arch Surg 2003;138:1362–1366CrossRefPubMedGoogle Scholar
  6. 6.
    Burningham AR, Krishnan J, Davidson BJ, et al. Papillary and follicular variant of papillary carcinoma of the thyroid: initial presentation and response to therapy. Otolaryngol Head Neck Surg 2005;132:840–844CrossRefPubMedGoogle Scholar
  7. 7.
    Carcangiu ML, Zampi G, Pupi A, et al. Papillary carcinoma of the thyroid: a clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 1985;55:805–828PubMedGoogle Scholar
  8. 8.
    Falvo L, Catanio A, D’Andrea V, et al. Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma. Ann Surg 2005;241:640–646CrossRefPubMedGoogle Scholar
  9. 9.
    Lloyd RV, DeLellis RA, Heitz PU, et al. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs, IARC (International Agency for Research on Cancer) Press, Lyons, France, 2004Google Scholar
  10. 10.
    Lloyd RV, Erickson LA, Casey MB, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004;28:1336–1340PubMedGoogle Scholar
  11. 11.
    Lo CY, Chan WF, Lam KY, et al. Optimizing the treatment of AMES high-risk papillary thyroid carcinoma. World J Surg 2004;28:1103–1109CrossRefPubMedGoogle Scholar
  12. 12.
    Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104:947–953PubMedGoogle Scholar
  13. 13.
    UICC (International Union Against Cancer). TNM Classification of Malignant Tumor, 5th ed. (Editors: Sobin LH, Wittlekind C), New York, Wiley-Liss, 1997Google Scholar
  14. 14.
    DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metabol 1990;71:414–424CrossRefGoogle Scholar
  15. 15.
    Hay ID, Bergstrath EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 to 1989. Surgery 1993;114:1056–1058Google Scholar
  16. 16.
    LiVolsi VA. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 2003;98:1997; author reply 1997–1998CrossRefPubMedGoogle Scholar
  17. 17.
    Baloch ZW, LiVolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol 2002;117:143–150CrossRefPubMedGoogle Scholar
  18. 18.
    Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: an unusually high prevalence of ras mutations. Am J Clin Pathol 2003;120:71–77CrossRefPubMedGoogle Scholar
  19. 19.
    Trovisco V, de Castro IV, Soares P, et al. BRAF mutations are associated with some histiotypes of papillary thyroid carcinoma. J Pathol 2004;202:247–251CrossRefPubMedGoogle Scholar
  20. 20.
    Lo CY, Lam KY, Leung PP, et al. High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma. Eur J Endocrinol 2005:152:545–550CrossRefPubMedGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2006

Authors and Affiliations

  • Brian Hung-Hin Lang
    • 1
  • Chung-Yau Lo
    • 1
    Email author
  • Wai-Fan Chan
    • 1
  • Alfred King-Yin Lam
    • 2
  • Koon-Yat Wan
    • 3
  1. 1.Department of SurgeryUniversity of Hong Kong Medical Centre, Queen Mary HospitalHong KongChina
  2. 2.Discipline of Pathology, School of MedicineGriffith UniversityGold CoastAustralia
  3. 3.Department of Clinical OncologyUniversity of Hong Kong Medical Centre, Queen Mary HospitalHong KongChina

Personalised recommendations